

IN THE CLAIMS

Please amend claims 1, 10, and 15 as follows.

Please cancel claim 11 without prejudice or disclaimer.

This listing of the claims replaces all prior versions of the claims in the application.

1. (Currently Amended) An isolated polypeptide selected from the group consisting of:
 - a) a polypeptide comprising an amino acid sequence of SEQ ID NO:5, and
 - b) a polypeptide comprising a naturally occurring amino acid sequence having at least ~~90%~~ 95% sequence identity to an amino acid sequence of SEQ ID NO:5, said polypeptide having UDP-glucuronosyltransferase activity,
 - ~~c) a polypeptide comprising a biologically active fragment of an amino acid sequence SEQ ID NO:5, and~~
 - ~~d) a polypeptide consisting of an immunogenic fragment of an amino acid sequence of SEQ ID NO:5.~~
2. (Previously Presented) An isolated polypeptide of claim 1 comprising an amino acid sequence of SEQ ID NO:5.
3. (Original) An isolated polynucleotide encoding a polypeptide of claim 1.
4. (Previously Presented) An isolated polynucleotide of claim 3 comprising a polynucleotide sequence of SEQ ID NO:10.
5. (Original) A recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide of claim 3.
6. (Original) A cell transformed with a recombinant polynucleotide of claim 5.
7. (Canceled)

- b) detecting the presence or absence of said hybridization complex, and, optionally, if present, the amount thereof.

13-14. (Canceled)

15. (Currently Amended) A pharmaceutical composition comprising ~~an effective amount of~~ a polypeptide of claim 1 and a pharmaceutically acceptable excipient.

16-19. (Canceled)

20. (Withdrawn) A method for screening a compound for effectiveness as an antagonist of a polypeptide of claim 1, the method comprising:

- a) exposing a sample comprising a polypeptide of claim 1 to a compound, and
- b) detecting antagonist activity in the sample.

21-22. (Canceled)

23. (Withdrawn) A method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a sequence of claim 4, the method comprising:

- a) exposing a sample comprising the target polynucleotide to a compound, and
- b) detecting altered expression of the target polynucleotide.

24. (Withdrawn) A method of screening for a compound that specifically binds to the polypeptide of claim 1, the method comprising:

- a) combining the polypeptide of claim 1 with at least one test compound under suitable conditions, and
- b) detecting binding of the polypeptide of claim 1 to the test compound, thereby identifying a compound that specifically binds to the polypeptide of claim 1.

25. (Withdrawn) A microarray wherein at least one element of the microarray is a polynucleotide of claim 11.

26. (Withdrawn) A method of generating an expression profile of a sample which contains polynucleotides, the method comprising:

- a) labeling the polynucleotides of the sample,
- b) contacting the elements of the microarray of claim 25 with the labeled polynucleotides of the sample under conditions suitable for the formation of a hybridization complex, and
- c) quantifying the expression of the polynucleotides in the sample.

27. (Withdrawn) A method of detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 10, the method comprising:

- a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and
- b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.

28. (Withdrawn) A method of assessing toxicity of a test compound, the method comprising:

- a) treating a biological sample containing nucleic acids with the test compound,
- b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 20 contiguous nucleotides of a polynucleotide of claim 10 under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide comprising a polynucleotide sequence of a polynucleotide of claim 10 or fragment thereof,
- c) quantifying the amount of hybridization complex, and
- d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample,

wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.

29. (Withdrawn) A method of screening for a compound that modulates the activity of the polypeptide of claim 1, the method comprising:

- a) combining the polypeptide of claim 1 with at least one test compound under conditions permissive for the activity of the polypeptide of claim 1,
- b) assessing the activity of the polypeptide of claim 1 in the presence of the test compound, and
- c) comparing the activity of the polypeptide of claim 1 in the presence of the test compound with the activity of the polypeptide of claim 1 in the absence of the test compound, wherein a change in the activity of the polypeptide of claim 1 in the presence of the test compound is indicative of a compound that modulates the activity of the polypeptide of claim 1.